Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
5-Amino-1MQ (5A1MQ) is a metabolic peptide, at the preclinical stage in the published literature. Small molecule NNMT inhibitor that may enhance fat metabolism and improve metabolic health through epigenetic mechanisms.
Small molecule NNMT inhibitor that may enhance fat metabolism and improve metabolic health through epigenetic mechanisms.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Oral |
| Doses Reported in Published Studies | 50-150 mg oral |
Inhibits nicotinamide N-methyltransferase (NNMT), increasing NAD+ levels and improving fat cell metabolism.
Small molecule NNMT inhibitor that may enhance fat metabolism and improve metabolic health through epigenetic mechanisms.
Inhibits nicotinamide N-methyltransferase (NNMT), increasing NAD+ levels and improving fat cell metabolism.
5-Amino-1MQ is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Oral. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.